Variable | 1 Month | 3 Months | ||||
---|---|---|---|---|---|---|
Continence (N = 264) | Incontinence (N = 386) | P value | Continence (N = 396) | Incontinence (N = 254) | P value | |
Age (years) | 65.60 ± 7.04 | 65.63 ± 7.94 | 0.959 | 65.20 ± 7.32 | 66.27 ± 7.94 | 0.080 |
BMI (kg/m2) | 24.85 ± 2.75 | 25.14 ± 2.98 | 0.209 | 25.01 ± 2.82 | 25.02 ± 3.01 | 0.964 |
Comorbidities, no (%) | ||||||
HP | 77 (29.17%) | 141 (36.53%) | 0.051 | 122 (30.81%) | 96 (37.80%) | 0.066 |
DM | 38 (14.39%) | 77 (16.06%) | 0.563 | 64 (16.16%) | 36 (14.17%) | 0.493 |
CHD | 20 (7.58%) | 43 (11.14%) | 0.131 | 38 (9.60%) | 25 (9.84%) | 0.917 |
CD | 9 (3.41%) | 11 (2.85%) | 0.685 | 10 (2.53%) | 10 (3.94%) | 0.309 |
PSA (ng/mL) | 27.65 ± 32.92 | 32.11 ± 36.08 | 0.109 | 28.65 ± 32.17 | 32.86 ± 38.64 | 0.133 |
PV (mL) | 37.73 ± 20.20 | 35.80 ± 18.58 | 0.211 | 37.15 ± 19.34 | 35.70 ± 19.15 | 0.348 |
Gleason score, no (%) | 0.475 | 0.654 | ||||
≤6 | 79 (29.92%) | 114 (29.53%) | 117 (29.55%) | 76 (29.92%) | ||
7 | 95 (35.98%) | 160 (41.45%) | 151 (38.13%) | 104 (40.94%) | ||
≥8 | 78 (29.55%) | 97 (25.13%) | 113 (28.54%) | 62 (24.41%) | ||
Unknown | 12 (4.55%) | 15 (3.89%) | 15 (3.78%) | 12 (4.73%) | ||
Clinical T stage, no (%) | 0.962 | 0.550 | ||||
T1a,b | 1 (0.37%) | 1 (0.26%) | 1 (0.25%) | 1 (0.39%) | ||
T1c | 46 (17.42%) | 68 (17.62%) | 69 (17.42%) | 45 (17.72%) | ||
T2a,b | 102 (38.64%) | 139 (36.01%) | 157 (39.65%) | 84 (33.07%) | ||
T2c | 103 (39.02%) | 155 (40.16%) | 149 (37.63%) | 109 (42.91%) | ||
T3a | 1 (0.37%) | 2 (0.51%) | 1 (0.25%) | 2 (0.79%) | ||
T3b | 11 (4.17%) | 21 (5.44%) | 19 (4.80%) | 13 (5.12%) | ||
OT (mins) | 151.61 ± 42.16 | 153.81 ± 48.78 | 0.551 | 151.02 ± 41.76 | 155.86 ± 52.30 | 0.192 |
NS, no (%) | 73 (27.65%) | 48 (12.44%) | 0.000 | 87 (21.97%) | 34 (13.39%) | 0.045 |
PLND, no (%) | 121 (45.83%) | 217 (56.22%) | 0.009 | 204 (51.52%) | 134 (52.76%) | 0.757 |
DIC (days) | 21.22 ± 10.83 | 21.02 ± 10.09 | 0.810 | 21.28 ± 11.46 | 20.84 ± 8.46 | 0.601 |